This segment focuses on the development of novel antibacterial agents to combat serious and life-threatening infections caused by multidrug-resistant bacteria. Research and development efforts are centered on identifying and optimizing new chemical entities with potent activity against Gram-negative pathogens, including Acinetobacter baumannii and Neisseria gonorrhoeae. The company employs advanced screening techniques, medicinal chemistry, and preclinical models to evaluate drug candidates. Clinical trials are conducted to assess the safety and efficacy of these agents in patients with pneumonia, bloodstream infections, and uncomplicated gonorrhea. The goal is to provide effective treatment options for infections where existing antibiotics are failing, thereby improving patient outcomes and reducing the spread of antimicrobial resistance. This segment includes SUL-DUR, Zoliflodacin, and ETX0462.